{
}
The Biden administration's proposed rule to expand access to obesity drugs for Medicare and Medicaid beneficiaries could significantly benefit Eli Lilly, whose shares rose alongside those of rival Novo Nordisk. In contrast, Amgen's stock plummeted over 11% after its weight-loss treatment, MariTide, fell short of expectations regarding effectiveness and safety. Meanwhile, President-elect Donald Trump plans to impose a 25% tariff on imports from Mexico and Canada, along with a 10% tariff on Chinese goods, raising questions about the U.S. stance on trade with China.
Amgen's experimental obesity drug, MariTide, demonstrated an average weight loss of up to 20% after one year in a mid-stage trial, with no observed plateau. The trial also explored various dosing regimens, including less frequent injections, as the company aims to compete in the growing obesity drug market. Despite promising results, Amgen's shares fell as the outcomes were at the lower end of expectations.
The Biden administration has proposed a rule to allow Medicare and Medicaid to cover popular weight-loss drugs like Wegovy and Ozempic for millions of obese Americans, potentially costing taxpayers up to $35 billion over the next decade. This move, aimed at treating obesity as a disease, could benefit an estimated 7.5 million additional people, although research suggests that around 28 million on Medicaid may qualify. Opposition from Robert F. Kennedy Jr., a nominee for HHS secretary, highlights a debate over whether to fund these drugs or invest in healthier food and gym memberships instead.
The Biden administration is proposing a rule to require government coverage for weight-loss drugs, potentially benefiting 3.4 million older Americans on Medicare and an additional four million in Medicaid. This move could significantly increase healthcare costs while expanding access to obesity treatments.
The Biden administration has proposed a rule to allow Medicare and Medicaid to cover weight loss drugs, potentially benefiting millions of Americans with obesity. This move, aimed at recognizing obesity as a chronic disease, could cost taxpayers around $36 billion over a decade, raising concerns about financial strain on these programs. The proposal's fate hinges on the incoming Trump administration's decision, amid mixed opinions from its appointed health officials.
Amgen's obesity drug, MariTide, demonstrated up to 20% weight loss in a Phase 2 trial, aligning with existing treatments like Zepbound and Wegovy. However, a higher dropout rate due to side effects raised concerns, leading to a decline in Amgen's stock. The company plans to initiate a Phase 3 study to further evaluate MariTide's efficacy and safety.
The Animal Healthcare Market is projected to grow significantly from 2024 to 2031, driven by evolving market dynamics and investment opportunities. The comprehensive report analyzes regional markets, competitive landscapes, and key players, providing insights into consumption trends, pricing strategies, and future growth prospects. Key segments include production and companion animals, with a focus on pharmaceuticals, vaccines, and feed additives.
The farm animal healthcare market is projected to grow from $19.77 billion in 2023 to $28.07 billion by 2028, driven by increasing livestock populations and rising global food demand. Key trends include advancements in biotechnology, digital health solutions, and eco-friendly practices. Major players in the market include Bayer AG, Merck & Co. Inc., and Zoetis Inc.
The North America oncology drugs market, valued at USD 10.13 billion in 2023, is projected to grow at a CAGR of 10.38%, reaching USD 27.20 billion by 2033. Key drivers include advances in cancer research, rising cancer prevalence, and increasing demand for personalized medicine, while challenges include high drug costs and stringent regulations. The market is segmented into cytotoxic, targeted, and hormonal drugs, with targeted therapies expected to dominate due to their effectiveness and reduced toxicity.
FDA Commissioner Robert Califf emphasized that the adoption of AI in healthcare is primarily driven by financial incentives rather than patient benefits, urging for continuous evaluation of AI tools to ensure their effectiveness. Meanwhile, Amazon is cautious about entering the GLP-1 market, prioritizing responsible practices over competition, while the DEA extends telehealth prescription allowances for controlled substances amid ongoing regulatory discussions.
Eli Lilly and Company
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
biden administration proposes obesity drug access amid market reactions and tariffs
United States Dollar
Amgen Inc.
Novo Nordisk A/S
Eli Lilly and Company
USA
CHN
CAN
Joe Biden
Donald Trump
Show more
15:07 26.11.2024
amgen's mariTide shows promise with up to 20 percent weight loss in trial
United States Dollar
Amgen Inc.
Novo Nordisk A/S
Eli Lilly and Company
USA
DNK
Jay Bradner
Show more
13:14 26.11.2024
biden administration proposes medicare medicaid coverage for weight loss drugs
United States Dollar
Novo Nordisk A/S
Eli Lilly and Company
USA
GBR
Robert F. Kennedy Jr.
Xavier Becerra
Donald Trump
Show more
11:40 26.11.2024
biden administration proposes coverage for obesity drugs under medicare medicaid
11:30 26.11.2024
biden administration proposes expanded medicare medicaid coverage for weight loss drugs
United States Dollar
UnitedHealth Group Incorporated
CVS
Eli Lilly and Company
Novo Nordisk A/S
Humana Inc.
USA
Robert F. Kennedy Jr.
Mehmet Oz
Chiquita Brooks-LaSure
Show more
01:00 26.11.2024
amgen obesity drug mariTide shows promise but falls short of expectations
United States Dollar
Amgen Inc.
Novo Nordisk A/S
Eli Lilly and Company
USA
David Risinger
Michael Yee
Show more
01:00 26.11.2024
comprehensive analysis of the animal healthcare market trends and key players
Novartis AG
Sanofi
DSM
Boehringer Ingelheim GmbH
Virbac SA
Merck & Co., Inc.
Zoetis Inc.
Bayer AG
Cargill Inc.
Eli Lilly and Company
USA
CAN
DEU
FRA
MEX
ITA
ARG
ZAF
SAU
RUS
ARE
ISR
GBR
BRA
Alice Mutum
Viju Shah
Show more
09:08 25.11.2024
farm animal healthcare market projected to reach 28 billion by 2028
14:32 22.11.2024
rth america oncology drugs market projected to reach 27.20 billion by 2033
United States Dollar
Novartis AG
Gilead Sciences, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Amgen Inc.
Bristol-Myers Squibb Company
Biogen Inc.
AstraZeneca PLC
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Celgene Corporation
AbbVie Inc.
Eli Lilly and Company
USA
Show more
14:29 22.11.2024
fda chief warns ai adoption driven by profits not patient care
Amazon.com, Inc.
Twitter
Eli Lilly and Company
USA
Nate Lacktman
Jack Dorsey
Anne Milgram
Robert Califf
Katie Palmer
Sunita Mishra
Ramy Farid
Show more
21:54 21.11.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Industry Trends
Global Trade Developments
Stock Market Updates
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Private Equity Deals
Government Economic Policies
Cryptocurrency Trends
Retail and Consumer Goods
Workplace Trends
Venture Capital Investments
Fintech Startups
CEO Changes
Central Bank Actions
Central Banks and Digital Currencies
Energy Sector Developments
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Tesla, Inc.
Tencent Holdings Ltd
Google Inc.
NIO Inc.
Nikkei 225
Nintendo Co., Ltd.
Grab2Go AS
OLA ELECTRIC MOBILITY LTD
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
New Taiwan Dollar
Indonesian Rupiah
Saudi Riyal
Offshore Chinese Yuan
Egyptian Pound
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
South Korean Won
Thai Baht
Mexican Peso
Croatian Kuna
Bahraini Dinar
People: